Literature DB >> 24667770

Species distribution and antifungal susceptibility profile of Candida isolates from bloodstream infections in Lima, Peru.

B Bustamante1, M A Martins2, L X Bonfietti2, M W Szeszs2, J Jacobs3, C Garcia1, M S C Melhem2.   

Abstract

Yeast identification and in vitro susceptibility testing provide helpful information for appropriate administration of antifungal treatments; however, few reports from the Latin American region have been published. The aim of this study was to identify the species present in isolates from bloodstream infections diagnosed in nine hospitals in Lima, Peru and to determine their in vitro susceptibility to four antifungal drugs. We tested and identified 153 isolates collected between October 2009 and August 2011 using standard methods. PCR and PCR-RFLP assays were performed to distinguish Candida albicans from Candida dubliniensis and to identify species of the Candida parapsilosis and Candida glabrata complexes. Antifungal susceptibility testing for fluconazole, anidulafungin and voriconazole was performed using the CSLI M27-A3 method, and amphotericin B susceptibility was determined using the Etest method. The most frequently isolated species were: C. albicans (61; 39.9 %), C. parapsilosis (43; 28.1 %), C. tropicalis (36; 23.5%) and C. glabrata (8; 5.2 %). The overall susceptibility rates were 98.0 %, 98.7 %, 98.0 % and 97.4 % for amphotericin B, fluconazole, voriconazole and anidulafungin, respectively. No isolate was resistant to more than one drug. These results showed that the rate of resistance to four antifungal drugs was low among Candida bloodstream isolates in Lima, Peru.
© 2014 The Authors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24667770     DOI: 10.1099/jmm.0.071167-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  10 in total

Review 1.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

2.  Current and promising pharmacotherapeutic options for candidiasis.

Authors:  Liliana Scorzoni; Beth Burgwyn Fuchs; Juliana Campos Junqueira; Eleftherios Mylonakis
Journal:  Expert Opin Pharmacother       Date:  2021-02-04       Impact factor: 3.889

3.  Resistance Surveillance in Candida albicans: A Five-Year Antifungal Susceptibility Evaluation in a Brazilian University Hospital.

Authors:  Isabela Haddad Peron; Franqueline Reichert-Lima; Ariane Fidelis Busso-Lopes; Cristiane Kibune Nagasako; Luzia Lyra; Maria Luiza Moretti; Angelica Zaninelli Schreiber
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

4.  Relationship between the Antifungal Susceptibility Profile and the Production of Virulence-Related Hydrolytic Enzymes in Brazilian Clinical Strains of Candida glabrata.

Authors:  Maria Helena Galdino Figueiredo-Carvalho; Lívia de Souza Ramos; Leonardo Silva Barbedo; Jean Carlos Almeida de Oliveira; André Luis Souza Dos Santos; Rodrigo Almeida-Paes; Rosely Maria Zancopé-Oliveira
Journal:  Mediators Inflamm       Date:  2017-07-26       Impact factor: 4.711

5.  A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes.

Authors:  Lourdes Rodriguez; Beatriz Bustamante; Luz Huaroto; Cecilia Agurto; Ricardo Illescas; Rafael Ramirez; Alberto Diaz; Jose Hidalgo
Journal:  PLoS One       Date:  2017-04-18       Impact factor: 3.240

6.  Increasing Incidence and Shifting Epidemiology of Candidemia in Greece: Results from the First Nationwide 10-Year Survey.

Authors:  Vasiliki Mamali; Maria Siopi; Stefanos Charpantidis; George Samonis; Athanasios Tsakris; Georgia Vrioni
Journal:  J Fungi (Basel)       Date:  2022-01-26

Review 7.  Invasive Candidiasis: Update and Current Challenges in the Management of This Mycosis in South America.

Authors:  Fernando Oscar Riera; Juan Pablo Caeiro; Sofia Carla Angiolini; Cecilia Vigezzi; Emilse Rodriguez; Paula Alejandra Icely; Claudia Elena Sotomayor
Journal:  Antibiotics (Basel)       Date:  2022-06-30

8.  Pan-Echinocandin Resistant C. parapsilosis Harboring an F652S Fks1 Alteration in a Patient with Prolonged Echinocandin Therapy.

Authors:  Maria Siopi; Antonios Papadopoulos; Anastasia Spiliopoulou; Fotini Paliogianni; Nissrine Abou-Chakra; Maiken Cavling Arendrup; Christina Damoulari; Georgios Tsioulos; Efthymia Giannitsioti; Frantzeska Frantzeskaki; Iraklis Tsangaris; Spyros Pournaras; Joseph Meletiadis
Journal:  J Fungi (Basel)       Date:  2022-09-01

Review 9.  Revisiting Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates from Latin American Medical Centers.

Authors:  Daniel Archimedes da Matta; Ana Carolina Remondi Souza; Arnaldo Lopes Colombo
Journal:  J Fungi (Basel)       Date:  2017-05-17

10.  Two New Compounds Containing Pyridinone or Triazine Heterocycles Have Antifungal Properties against Candida albicans.

Authors:  Laura Mena; Muriel Billamboz; Rogatien Charlet; Bérangère Desprès; Boualem Sendid; Alina Ghinet; Samir Jawhara
Journal:  Antibiotics (Basel)       Date:  2022-01-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.